NTRA
Natera, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$363.76
−6.97%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$377.46
From 52W high−16.57%
Volume3.11M
Market cap$52.43B
P/E (TTM)—
P/S (TTM)19.4x
Div yield—
Key dataNov 5, 2026
Open
$377.46
From 52W high
−16.57%
Volume
3.11M
Market cap
$52.43B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−288.6x
P/E (TTM)
—
RSI (14)
39.5
MomentumView details →
1D Return
−6.97%
YTD Return
+59.33%
SummaryUpdated Jun 1, 2026
Natera, Inc. (NASDAQ:NTRA) is a molecular diagnostics company founded in 2003 and headquartered in Austin, Texas. Originally known as Gene Security Network, Inc., the company changed its name to Natera in 2012 and went public in 2015. Natera has evolved from a genetics-focused startup into a leading provider of genetic testing services across three primary healthcare segments: women's health, oncology, and organ health. The company develops and commercializes advanced molecular testing services that analyze DNA to provide critical medical information for patients and healthcare providers worldwide.
Similar companies
Latest newsMore news →
Natera reported third-quarter 2026 revenue of $794.0 million, up 34.1% from $592.2 million a year earlier, and a gross margin of 64.7%, compared with 64.9%.9h agoNatera announced three peer-reviewed publications highlighting the clinical performance and actionability of its Signatera test in head and neck squamous cell carcinoma.2d agoThe U.S. Food and Drug Administration granted Breakthrough Device designation to Natera's multi-cancer early detection assay.28d ago